| | Reference, year | n | Sex (♂,♀) | Age (med, range) | Prior therapies | Combined therapies | Pathology diagnosis | Stage | Response | PEG-IFN dose | PEG-IFN treatment duration in weeks (median, range) | Reasons for discontinuation (if applicable) | Adverse effects | Outcome | Comments |
| | Walker et al., 2021 [25] | 7 | 4, 3 | 58, 38–79 | TCS, topical nitrogen mustard, NB-UVB, local radiation therapy, total skin electron beam therapy, alemtuzumab, MTX, topical calcipotriene/betamethasone, cyclosporine, systemic steroids | Phototherapy | 5, MF | IIB or higher | 1, CR | 1.5 μg/kg/week–9 μg/kg/week | 10, 2–40 | Disease progression, heart failure, neutropenia, infection | Constitutional symptoms (100% of patients) | Progression-free survival median, 3.5 months | Patients had no previous interferon therapy. Study concluded that the dose of 9 μg/kg of PEG-IFN is too high and the clinicians employ a dose of 1.5 μg/kg | | 2, SS | 4, PR | Average dose = 3.76 μg/kg/week | Hematologic abnormalities (100% of patients) | 6 dead | | 2, SD | 1 alive |
| | Schiller et al., 2017 [26] | 4 | 4.0 | 64.5, 33–71 | PUVA, TCS, retinoids | None | MF | 1, IA | 2, CR | 180 μg/week | 12 | | 75% of patients experienced at least 1 AE | | One case of dose-limiting toxicity due to grade 3 elevation of liver enzymes. Dose-related increase in clinical response was not demonstrated | | 3, IB | 2, SD | Hematologic abnormalities, liver toxicity | | 6 | 5.1 | 58.5, 48–74 | PUVA, TCS, IFN, retinoids | None | MF | 4, IA | 4, CR | 270 μg/week | 12 | | 83% of patients experienced at least 1 AE. Hematologic abnormalities, constitutional symptoms, liver toxicity, GI symptoms | | | 2, IB | 1, PR | | 1, SD | | 3 | 2.1 | 59, 29–74 | PUVA, TCS, retinoids | None | MF | 2, IA | 1, CR | 360 μg/week | 12 | | 100% of patients experienced at least 1 AE. Hematologic abnormalities, constitutional symptoms, liver toxicity, GI symptoms | | | 1, IB | 1, PR | | 1, SD | | Hüsken et al., 2012 [24] | 9 | 8.1 | 58.75, 36–75 | PUVA ± IFN α-2a | PUVA | MF | 2, IA | 4, CR | Intended 1.5 μg/kg/week | 42.9, 8–82 | Disease progression (1), toxicity (2), 1 CTC grade, (3) depression, (1) exacerbation of psoriasis, one dose modification due to grade III constitutional side-effects | Constitutional, 77.8% | Progression free survival 30.96 ± 4.9 months | Comparison between PEG-IFN + PUVA and IFN + PUVA showed overall response (CR + PR), which was higher in the PEG-IFN group (88.8%. vs. 50%) | | 3, IB | 4, PR | Mean = 1 μg/kg/week (mean cumulative dose of 3562.2 μg) | Neuropsychiatric, 55.5% | 5-year relapse-free survival 75% | | 2, IIA/IIB | 1, PD | | Gastrointestinal, 77.8% | | 1, III | | Hepatotoxicity, 77.8% | | 1, IV | Myelosuppression, 77.8% |
| | Fujimura et al., 2007 [27] | 1 | 1.0 | 60 | PUVA, retinoids, intralesional IFN-γ | None | MF | | CR | 180 μg/week | 2 years | | None reported | Alive | |
| | Yanagi et al., 2006 [28] | 1 | 1.0 | 67 | TCS, PUVA, retinoids | Oral ribavirin, continued PUVA and retinoids for 4 weeks after initiation of PEG-IFN | MF | Plaque stage | CR | 80 μg/week | 4 weeks | | None reported | Alive | Patient had chronic HCV infection, which was primary reason for initiation of PEG-IFN + ribavirin |
| | Fujimura et al., 2006 [29] | 1 | 0.1 | 72 | Total body electron beam therapy | None | CD8+ MF | | CR after reinitiating PEG-IFN | 180 μg/week | 6 weeks | Liver enzyme elevation (ALT 165 IU/L), grade I | Hepatotoxicity | | CD8+ MF was preceded by parapsoriasis en plaque |
| | Patstati et al., 2021 [30] | 31 | 19.12 | 62.6 | Not specified, PEG-IFN was 3rd line treatment in 21 patients, 2nd line in 8, 1st line in 2 | 11, monotherapy with PEG-IFN | MF (26), folliculotropic MF (5) | 5, IA | 3, CR | 135 μg/week (9) 180 μg/week (22) | Mean duration was 3.4 months prior to discontinuation in 9 patients. 8 reduced dose due to intolerance | | Neutropenia (16), fatigue (9), anemia (4) | | In cohort of 13 patients who switched from IFN-α-2a to PEG-IFN, 4 presented with fatigue and neutropenia | | 4, baroxetene | 12, IB | 14, PR | | 4, acitretin | 1, IIA | 2, PD | | 4, MTX | 7, IIB | 11, SD | | 8, topical chemotherapy | 3, III
3, IV | 1, discontinued | | Lampadaki, 2021 [31] | 1 | 0.1 | 70 | PUVA + clobetasol | Clobetasol, chlormethine gel | Folliculotropic MF | IB | PR | 180 μg/week | Ongoing (as of publication) | | | Alive | The use of chlormethine gel was highlighted in this publication as an additional therapy for patients with stage IB and IIB MF who have failed previous treatment | | Acitretin | | TSEC | | IFN-α | | MTX | | 1 | 1.0 | 66 | IFN-α-2b + clobetasol | Clobetasol, chlormethine gel | Folliculotropic MF | IIB | CR | 180 μg/week | Ongoing (as of publication) | | | Alive | | MTX + clobetasol |
| | Bakar et al., 2015 [32] | 1 | 0.1 | 33 | TCS | PUVA | MF | IA | PR | 50 μg/m2/week | 7.5 months ongoing (as of publication) | | | Alive | Case report of a patient with tumor-stage MF of the vulva treated with local RT followed by IFN and then transitioned to PEG-IFN | | NBUVB | | PUVA | | Acitretin | | Local RT + total body NBUVB | | IFN-α |
|
|
